

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of  
CHANG et al.

Customer No.: 51957

Serial No: 10/685,941

Filed: October 14, 2003

For: COMBINATION OF BRIMONIDINE  
AND TIMOLOL FOR TOPICAL  
OPHTHALMIC USE

Group Art Unit: 1614

Examiner: Brian S. Kwon

Confirmation No. 7685

FILED ELECTRONICALLY

Commissioner for Patents  
Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith is a Reply to the Office Action dated February 13, 2007 on the above-identified application.

☒ Reply (4 pages)

☒ The fee has been calculated as shown below.

☒ Terminal Disclaimer and fee of \$30.00 (2 pages)

☒ Declaration of an Expert (4 pages)

<i>CLAIMS</i>	<b>COLUMN A</b> <i>Claims Remaining After Amendment</i>	<b>COLUMN B</b> <i>Highest Number Previously Paid</i>	<b>COLUMN C</b> <i>Present Extra</i>	<i>Rate</i>	<i>Additional Fee</i>
<i>Total</i>	1	20	0	x \$50	\$ .00
<i>Independent</i>	1	3	0	x \$200	\$ .00
<input type="checkbox"/> First Presentation of Multiple Dep. Claim x \$280 = \$ .00					
Time Extension Fees:					\$ .00
Terminal Disclaimer Fee					\$130
Total Due:					\$130.00

The Commissioner is hereby authorized to charge payment of any additional fees required under 37 CFR 1.16, or credit any overpayment, to Deposit Account No. 01-0885.

Date: March 8, 2007

/Brent A. Johnson/

Brent A. Johnson

Registration No. 51,851

ALLERGAN, INC. (T2-7H)

2525 Dupont Drive

Irvine, CA 92612

Telephone No. (714) 246-4348

Telecopier: (714) 246-4249